- Home
- KLTO vs CNSP Comparison
KLTO vs CNSP Comparison
Compare KLTO & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTO
- CNSP
- Stock Information
- Founded
- KLTO 2019
- CNSP 2017
- Country
- KLTO United States
- CNSP United States
- Employees
- KLTO N/A
- CNSP N/A
- Industry
- KLTO
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- KLTO
- CNSP Health Care
- Exchange
- KLTO NYSE
- CNSP Nasdaq
- Market Cap
- KLTO 5.9M
- CNSP 5.6M
- IPO Year
- KLTO N/A
- CNSP 2019
- Fundamental
- Price
- KLTO $1.34
- CNSP $0.86
- Analyst Decision
- KLTO
- CNSP Hold
- Analyst Count
- KLTO 0
- CNSP 1
- Target Price
- KLTO N/A
- CNSP N/A
- AVG Volume (30 Days)
- KLTO 22.5M
- CNSP 178.2K
- Earning Date
- KLTO 08-15-2025
- CNSP 08-13-2025
- Dividend Yield
- KLTO N/A
- CNSP N/A
- EPS Growth
- KLTO N/A
- CNSP N/A
- EPS
- KLTO N/A
- CNSP N/A
- Revenue
- KLTO N/A
- CNSP N/A
- Revenue This Year
- KLTO N/A
- CNSP N/A
- Revenue Next Year
- KLTO N/A
- CNSP N/A
- P/E Ratio
- KLTO N/A
- CNSP N/A
- Revenue Growth
- KLTO N/A
- CNSP N/A
- 52 Week Low
- KLTO $0.11
- CNSP $0.73
- 52 Week High
- KLTO $3.91
- CNSP $82.50
- Technical
- Relative Strength Index (RSI)
- KLTO N/A
- CNSP 48.03
- Support Level
- KLTO N/A
- CNSP $0.85
- Resistance Level
- KLTO N/A
- CNSP $0.95
- Average True Range (ATR)
- KLTO 0.00
- CNSP 0.08
- MACD
- KLTO 0.00
- CNSP 0.02
- Stochastic Oscillator
- KLTO 0.00
- CNSP 59.17
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.